Journal article icon

Journal article

The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled tria

Abstract:

Background
Guselkumab, a fully human monoclonal antibody targeting the interleukin (IL)-23p19 subunit, is approved to treat adults with active psoriatic arthritis (PsA). In the Phase 3 DISCOVER-2 trial of 739 bilogico-naïve patients with active PsA, guselkumab 100 mg resulted in less radiographic progression, assessed via change from baseline in PsA-modified van der Heijde-Sharp (vdH-S) score, compared with placebo at week (W) 24 when given at W0, W4, and then every 4 ...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1186/s13063-022-06945-y

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Role:
Author
Publisher:
BioMed Central
Journal:
Trials More from this journal
Volume:
24
Issue:
1
Article number:
22
Publication date:
2023-01-10
Acceptance date:
2022-11-18
DOI:
EISSN:
1745-6215
Language:
English
Keywords:
Pubs id:
1307696
Local pid:
pubs:1307696
Deposit date:
2022-11-22

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP